352 related articles for article (PubMed ID: 27984005)
21. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Cushman WC; Ford CE; Einhorn PT; Wright JT; Preston RA; Davis BR; Basile JN; Whelton PK; Weiss RJ; Bastien A; Courtney DL; Hamilton BP; Kirchner K; Louis GT; Retta TM; Vidt DG;
J Clin Hypertens (Greenwich); 2008 Oct; 10(10):751-60. PubMed ID: 19090876
[TBL] [Abstract][Full Text] [Related]
22. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Dewland TA; Soliman EZ; Yamal JM; Davis BR; Alonso A; Albert CM; Simpson LM; Haywood LJ; Marcus GM
Circ Arrhythm Electrophysiol; 2017 Dec; 10(12):. PubMed ID: 29212812
[TBL] [Abstract][Full Text] [Related]
23. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber MA; Franklin S; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T;
Ann Intern Med; 2006 Feb; 144(3):172-80. PubMed ID: 16461961
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Dhruva SS; Huang C; Spatz ES; Coppi AC; Warner F; Li SX; Lin H; Xu X; Furberg CD; Davis BR; Pressel SL; Coifman RR; Krumholz HM
Hypertension; 2017 Jul; 70(1):94-102. PubMed ID: 28559399
[TBL] [Abstract][Full Text] [Related]
27. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT;
Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749
[TBL] [Abstract][Full Text] [Related]
28. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).
Alderman MH; Davis BR; Piller LB; Ford CE; Baraniuk MS; Pressel SL; Assadi MA; Einhorn PT; Haywood LJ; Ilamathi E; Oparil S; Retta TM;
Am J Cardiol; 2016 Jan; 117(1):105-15. PubMed ID: 26589819
[TBL] [Abstract][Full Text] [Related]
29. Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Piller LB; Ford CE; Davis BR; Nwachuku C; Black HR; Oparil S; Retta TM; Probstfield JL;
J Clin Hypertens (Greenwich); 2006 Sep; 8(9):649-56; quiz 657-8. PubMed ID: 16957427
[TBL] [Abstract][Full Text] [Related]
30. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Davis BR; Kostis JB; Simpson LM; Black HR; Cushman WC; Einhorn PT; Farber MA; Ford CE; Levy D; Massie BM; Nawaz S;
Circulation; 2008 Nov; 118(22):2259-67. PubMed ID: 19001024
[TBL] [Abstract][Full Text] [Related]
31. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Cushman WC; Davis BR; Pressel SL; Cutler JA; Einhorn PT; Ford CE; Oparil S; Probstfield JL; Whelton PK; Wright JT; Alderman MH; Basile JN; Black HR; Grimm RH; Hamilton BP; Haywood LJ; Ong ST; Piller LB; Simpson LM; Stanford C; Weiss RJ;
J Clin Hypertens (Greenwich); 2012 Jan; 14(1):20-31. PubMed ID: 22235820
[TBL] [Abstract][Full Text] [Related]
32. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
Cushman WC; Ford CE; Cutler JA; Margolis KL; Davis BR; Grimm RH; Black HR; Hamilton BP; Holland J; Nwachuku C; Papademetriou V; Probstfield J; Wright JT; Alderman MH; Weiss RJ; Piller L; Bettencourt J; Walsh SM;
J Clin Hypertens (Greenwich); 2002; 4(6):393-404. PubMed ID: 12461301
[TBL] [Abstract][Full Text] [Related]
33. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
[TBL] [Abstract][Full Text] [Related]
34. Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
Du XL; Simpson LM; Tandy BC; Bettencourt JL; Davis BR
PLoS One; 2021; 16(11):e0260107. PubMed ID: 34793552
[TBL] [Abstract][Full Text] [Related]
35. Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Johnson K; Oparil S; Davis BR; Tereshchenko LG
J Am Heart Assoc; 2019 Apr; 8(8):e011961. PubMed ID: 30943832
[TBL] [Abstract][Full Text] [Related]
36. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease.
Dewland TA; Soliman EZ; Davis BR; Magnani JW; Yamal JM; Piller LB; Haywood LJ; Alonso A; Albert CM; Marcus GM;
JAMA Intern Med; 2016 Aug; 176(8):1085-92. PubMed ID: 27367818
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
Piller LB; Simpson LM; Baraniuk S; Habib GB; Rahman M; Basile JN; Dart RA; Ellsworth AJ; Fendley H; Probstfield JL; Whelton PK; Davis BR;
J Gen Intern Med; 2014 Nov; 29(11):1475-83. PubMed ID: 25002161
[TBL] [Abstract][Full Text] [Related]
38. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group
Hypertension; 2003 Sep; 42(3):239-46. PubMed ID: 12925554
[TBL] [Abstract][Full Text] [Related]
39. Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.
Wang SY; Hanna JM; Gongal P; Onuma OK; Nanna MG
Am Heart J; 2022 Dec; 254():30-34. PubMed ID: 35932912
[TBL] [Abstract][Full Text] [Related]
40. Recommendations for the management of special populations: racial and ethnic populations.
Ferdinand KC
Am J Hypertens; 2003 Nov; 16(11 Pt 2):50S-54S. PubMed ID: 14625162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
